MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, November 28, 2015

Opexa Therapeutics’ MS Therapy Selected as ‘Top Project to Watch’

<span class="entry-title">Opexa Therapeutics’ MS Therapy Selected as ‘Top Project to Watch’</span><span class="entry-subtitle">Company's work in personalized immunotherapies honored for 3rd consecutive year</span>

Company's work in personalized immunotherapies honored for 3rd consecutive year

Opexa Therapeutics, Inc., announced that it has been named one of the “Top Projects to Watch” for the third consecutive year. A panel of independent experts recognized the biopharmaceutical company for its work in the development of personalized immunotherapies for autoimmune disorders, such as multiple sclerosis (MS) and neuromyelitis optica (NMO).
Opexa was among eight companies whose efforts in six therapeutic areas were selected as top projects, out of hundreds of compounds considered by the panel for their potential as products. The selection was announced at the recent Therapeutic Area Partnerships meeting in Boston, where Opexa’s President and CEO Neil K. Warma presented an overview of his company.
“Selected companies…  represent what our committees consider among the most attractive opportunities the industry has to offer,” Marc Wortman, Editorial Director at Therapeutic Area Partnerships, said in a press release. “Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”
read more


Keep up to date with the news and information we provide 
by signing up by clicking here

No comments: